Navigation Links
BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
Date:2/18/2009

    NOVATO, Calif., Feb. 18 /PRNewswire-FirstCall/ --

    Financial Highlights ($ in millions, except per share data)

    Item                         FY 2008           FY 2007 Comparison
    Total BioMarin Revenue        $296.5            143.9% increase
    Naglazyme Net Product
     Revenue                      $132.7            53.9% increase
    Aldurazyme Net Sales by
     Genzyme                      $151.3            22.3% increase
    Aldurazyme BioMarin Net
     Product Revenue              $72.5             NA
    Kuvan Net Product Revenue     $46.7             $0.4
    GAAP Net Income (Loss)        $30.8             ($15.8)
    GAAP Net Income (Loss)
     per share                    $0.31 (basic),   ($0.16) (basic and diluted)
                                  $0.29 (diluted)
    Non-GAAP Net Income (Loss)    $56.1             $2.5
    Non-GAAP Net Income (Loss)
     per share                    $0.57 (basic),    $0.03 (basic and diluted)
                                  $0.52 (diluted)


BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced financial results for the fourth quarter and year ended December 31, 2008. Net income was $24.5 million ($0.21 per fully diluted share) for the fourth quarter of 2008, compared to net income of $2.6 million ($0.03 per fully diluted share) for the fourth quarter of 2007. Non-GAAP net income was $31.9 million ($0.27 per fully diluted share) for the fourth quarter of 2008, compared to non-GAAP net income of $8.1 million ($0.08 per fully diluted share) for the fourth quarter of 2007. Non-GAAP net income/loss excludes non-cash stock compensation expense, which was $7.4 million for the three months ended December 31, 2008 and $5.5 million for the three months ended December 31, 2007.

Net income for the year ended December 31, 2008 was $30.8 million ($0.29 per fully diluted share), compared to a net loss of $15.8 million ($0.16 per fully diluted share) for the year ended December 31, 2007. Non-GAAP net income was $56.1 million ($0.52 per fully diluted share) for the year ended December 31, 2008, compared to non-GAAP net income of $2.5 million ($0.03 per fully diluted share) for the year ended December 31, 2007. Non-cash stock compensation expense for the year ended December 31, 2008 and December 31, 2007 was $25.3 million and $18.3 million, respectively.

As of December 31, 2008, BioMarin had cash, cash equivalents, and short-term investments totaling $559.8 million.

"We achieved our first profitable full year in 2008, with an increase of 144 percent in total revenue over 2007 driven by our three growing commercial products. We ended the year with a strong cash position and a promising development pipeline," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "In 2009, we look forward to the advancement of several programs including PEG-PAL for PKU and GALNS for MPS IVA. We also plan to continue making investments in growth opportunities as we look for attractive in- licensing or acquisition opportunities."

Net Product Revenue

Net product revenue from Naglazyme (galsulfase), an enzyme replacement therapy for mucopolysaccharidosis VI (MPS VI), was $36.5 million for the fourth quarter of 2008, an increase of 43.1 percent compared to Naglazyme net product revenue of $25.5 million for the fourth quarter of 2007. Net product revenue from Naglazyme for the year ended December 31, 2008 was $132.7 million, an increase of 53.9 percent from Naglazyme net product revenue of $86.2 million for the year ended December 31, 2007.

Net sales of Aldurazyme (laronidase), an enzyme replacement therapy for mucopolysaccharidosis I (MPS I) recorded by Genzyme, were $37.6 million for the fourth quarter of 2008, an increase of 6.2 percent compared to net sales by Genzyme of $35.4 million for the fourth quarter of 2007. Net sales of Aldurazyme recorded by Genzyme for the year ended December 31, 2008 were $151.3 million, an increase of 22.3 percent compared to net sales by Genzyme of $123.7 million for the year ended December 31, 2007.

Net product revenue to BioMarin related to Aldurazyme was $14.4 million for the fourth quarter of 2008. This reflects a reduction in net product revenue from the royalty payable to BioMarin by Genzyme due to the timing of inventory transfers to Genzyme, which were less than units shipped to third party customers by Genzyme during the fourth quarter of 2008. Net product revenue to BioMarin related to Aldurazyme was $72.5 million for the year ended December 31, 2008, which included $12.4 million of net incremental product transfer revenue during 2008.

Beginning January 1, 2008, as a result of the restructuring of the joint venture with Genzyme, BioMarin receives a royalty of 39.5% to 50% of worldwide net sales. BioMarin recognizes a portion of this amount as product transfer revenue when product is released to Genzyme. This amount will eventually be credited against the calculated royalties earned when the product is sold by Genzyme to third parties.

Net product revenue from Kuvan (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), was $15.1 million for the fourth quarter of 2008 and $46.7 million for the year ended December 31, 2008.

Collaborative Agreement Revenues

Collaborative agreement revenues for the fourth quarter of 2008 were $31.5 million and included the $30 million milestone payment from Merck Serono for Kuvan marketing approval in the E.U., compared to $17.5 million for the fourth quarter of 2007 which included the $15 million milestone payment from Merck Serono for the filing of the MAA for Kuvan. Collaborative agreement revenues for the year ended December 31, 2008 were $38.9 million, compared to $28.3 million for the year ended December 31, 2007.

Impairment Loss on Investments

In the fourth quarter of 2008, BioMarin recorded an impairment charge of $4.1 million for the decline in the value of its equity investment in Summit Corporation plc. Based on the current market conditions, the low volume of trading in Summit securities and its current financial condition, BioMarin determined that its investment in Summit was impaired as of year end and adjusted the recorded amount of its investment to the stock's market price on December 31, 2008. The remaining investment in Summit Corporation plc. of $1.6 million is reflected on the balance sheet as of December 31, 2008.



    2009 Guidance
    Revenue Guidance ($ in millions)

    Item                                          2009 Guidance    2008 Actual
    Total BioMarin Revenues                       $307 to $336     $296.5
    Total Net Product Revenues                    $300 to $329     $251.9
    Naglazyme Net Product Revenue                 $160 to $175     $132.7
    Kuvan Net Product Revenue                     $70 to $80       $46.7
    Aldurazyme Net Product Revenue to BioMarin*   $69 to $74       $72.5


    *  The 2009 Aldurazyme guidance, as compared to 2008, reflects increased
       royalties earned offset by a reduction of $7 million to $9 million in
       net incremental product transfer revenue, mostly related to the initial
       inventory transfer.



    Selected Income Statement Guidance ($ in millions)

    Item                                       Guidance
    Cost of Sales (% of Total Revenue)         19% to 21%
    Selling, General and Admin. Expense        $120 to $130
    Research and Development Expense*          $110 to $120
    Costs Associated with Riquent Deal**       Up to $15
    Interest Income                            $5 to $7
    Net Income (Loss) (GAAP)                   $(15) to $0
    Stock Compensation Expense                 $32 to $35
    Net Income (non-GAAP)                      $17 to $35

    *   Excludes upfront research and development expenses associated with the
        Riquent deal
    **  Represents upfront costs associated with the Riquent deal to be
        allocated between research and development expense and investment
        impairment


BioMarin estimates that top line product revenue will grow approximately 20% to 25% in 2010 and approximately 15% to 20% in 2011. These revenue estimates reflect growth from existing commercial products and do not include potential sales from additional new products. BioMarin expects GAAP net income in the range of $35 million to $40 million in 2010 and in the range of $60 million to $65 million in 2011. Excluding stock compensation expense, non-GAAP net income is projected to be in the range of $70 million to $80 million in 2010 and in the range of $95 million to $105 million in 2011. These estimates are based on BioMarin's current business plan and do not include the effect of any significant business development transaction that the company may choose to do in the future.

Non-GAAP Financial Information and Reconciliation

The above results for the fourth quarter and full year of 2007 and 2008 and financial guidance for 2009, 2010 and 2011 include actual and Management's 2009, 2010 and 2011 estimated net income, respectively, determined in accordance with GAAP and non-GAAP net income. As used in this release, non-GAAP income is net income calculated in accordance with GAAP, but excluding non-cash stock compensation expense, a non-GAAP financial measure. Stock compensation expense excluded in the calculation of non-GAAP net income was $7.4 million for the fourth quarter of 2008, $5.5 million for the fourth quarter of 2007, $25.3 million for the year ended December 31, 2008 and $18.3 million for the year ended December 31, 2007. Management estimates stock compensation expense of $32.0 million to $35.0 million in 2009, approximately $35.0 million to $40.0 million in 2010 and approximately $35.0 million to $40.0 million in 2011. The reconciliation of this measure to the estimated GAAP net income is as follows (in millions):



                              Year       Year
                             Ended      Ended
                 Q4    Q4   December   December    2009      2010       2011
                2008  2007  31, 2008   31, 2007  Guidance  Guidance   Guidance

    GAAP net
     income                                     $(15.0) -    $35.0 -   $60.0 -
     (loss)     $24.5  $2.6  $30.8    $(15.8)    $0           $40.0     $65.0
    Non-cash
     stock
     compensation                                 32.0 -      35.0 -    35.0 -
     expense      7.4   5.5   25.3      18.3       35.0        40.0      40.0
    Non-GAAP                                     $17.0 -     $70.0 -   $95.0 -
     net income $31.9  $8.1  $56.1      $2.5      $35.0       $80.0     $105.0


Management believes that this non-GAAP information is useful to investors, taken in conjunction with BioMarin's GAAP information because Management uses such information internally for its operating, budgeting and financial planning purposes, and to enhance investors' overall understanding of the company's prospects for the future.

Diluted Earnings Per Share Calculation

GAAP diluted earnings per share for the fourth quarter of 2008 and non-GAAP diluted earnings per share for the fourth quarter and full year 2008 includes 26.3 million shares related to the outstanding convertible debt. The calculation of GAAP diluted earnings per share for the fourth quarter of 2008 and non-GAAP diluted earnings per share for the fourth quarter and full year 2008 reflects the exclusion of the theoretical interest expense from net earnings that would no longer be incurred if the debt was converted into shares. For the full year 2008 GAAP diluted earnings per share and the fourth quarter and full year 2007 GAAP and non-GAAP diluted earnings per share, the 26.3 million shares related to the convertible debt are excluded from the diluted earnings per share calculation as their impact is considered anti-dilutive.

    Anticipated Upcoming Milestones
    --  1Q09: Results from BH4+Vitamin C study
    --  1Q09: Results from Phase 2 PAH trial
    --  1Q09/2Q09: Initiation of Phase 1 trial for GALNS for MPS IVA
    --  2Q09: Results from proteinuria in chronic kidney disease trial
    --  2Q09: Results from PEG-PAL Phase 1 trial
    --  2Q09: Initiation of PEG-PAL Phase 2 trial


    Upcoming Investor Conferences and Events
    --  March 4-5: Credit Suisse Global Healthcare Conference
    --  March 10-11: Barclays Healthcare Conference
    --  March 16-18: Cowen Healthcare Conference
    --  April 1: Citi Biotech Day

BioMarin will host a conference call and webcast to discuss fourth quarter and full year 2008 financial results today, Wednesday, February 18, at 5:00 p.m. ET (22:00 CET). This event can be accessed on the investor section of the BioMarin website at http://www.BMRN.com.

    Date: February 18, 2009
    Time: 5:00 p.m. ET (22:00 CET)
    U.S. / Canada Dial-in Number:  866.700.6293
    International Dial-in Number:  617.213.8835
    Participant Code: 35749059
    Replay Dial-in Number: 888.286.8010
    Replay International Dial-in Number: 617.801.6888
    Replay Code: 73992450

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the expectations of revenue and sales related to Naglazyme, Kuvan, and Aldurazyme; the financial performance of the BioMarin as a whole; the timing of BioMarin's clinical trials of 6R-BH4 for other indications, PEG-PAL, GALNS and other product candidates; the continued clinical development and commercialization of Aldurazyme, Naglazyme, Kuvan, and its product candidates; and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the continued commercialization of Naglazyme and Kuvan; Genzyme Corporation's success in continuing the commercialization of Aldurazyme; results and timing of current and planned preclinical studies and clinical trials; our ability to successfully manufacture our products and product candidates; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for each of these products and particularly Aldurazyme, Naglazyme and Kuvan; actual sales of Aldurazyme, Naglazyme and Kuvan; Merck Serono's activities related to Kuvan; the results of the final analysis of the ASPEN trial by La Jolla Pharmaceuticals; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2007 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

    Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

     Contact:

     Investors                         Media
     Eugenia Shen                      Susan Berg
     BioMarin Pharmaceutical Inc.      BioMarin Pharmaceutical Inc.
     (415) 506-6570                    (415) 506-6594



                BIOMARIN PHARMACEUTICAL INC. AND SUBSIDIARIES

                         CONSOLIDATED BALANCE SHEETS
                          December 31, 2007 and 2008
             (In thousands, except for share and per share data)

                                                    December 31,  December 31,
                                                        2007          2008
                       ASSETS
    Current assets:
      Cash and cash equivalents                       $228,343      $222,900
      Short-term investments                           357,251       336,892
      Accounts receivable, net                          16,976        54,298
      Advances to BioMarin/Genzyme LLC                   2,087           174
      Inventory                                         32,445        73,162
      Other current assets                               7,195        50,270

        Total current assets                           644,297       737,696

    Investment in BioMarin/Genzyme LLC                  44,881           915
    Other investments                                       --         1,633
    Property, plant and equipment, net                  76,818       124,979
    Intangible assets, net                               9,596         7,626
    Goodwill                                            21,262        21,262
    Other assets                                        18,425        12,584

        Total assets                                  $815,279      $906,695


          LIABILITIES AND STOCKHOLDERS' EQUITY
    Current liabilities:
      Accounts payable and accrued liabilities         $49,907       $58,851
      Current portion of acquisition obligation,
       net of discount                                   6,309        70,741
      Deferred revenue                                   5,327           307
      Other current liabilities                             --           182

        Total current liabilities                       61,543       130,081

    Convertible debt                                   497,375       497,083
    Long-term portion of acquisition obligation,
     net of discount                                    66,553            --
    Other long-term liabilities                          2,082         2,856

        Total liabilities                              627,553       630,020

    Stockholders' equity:
      Common stock, $0.001 par value: 250,000,000
       shares authorized at December 31, 2007 and
       December 31, 2008; 97,114,159 and 99,868,145
       shares issued and outstanding at December 31,
       2007 and 2008, respectively                          97           100
      Additional paid-in capital                       794,917       852,947
      Company common stock held by deferred
       compensation plan                                    --          (882)
      Accumulated other comprehensive income               139         1,106
      Accumulated deficit                             (607,427)     (576,596)

        Total stockholders' equity                     187,726       276,675

        Total liabilities and stockholders' equity    $815,279      $906,695

         See accompanying notes to consolidated financial statements.



                BIOMARIN PHARMACEUTICAL INC. AND SUBSIDIARIES
                    CONSOLIDATED STATEMENTS OF OPERATIONS
      For the Three and Twelve Months Ended, December 31, 2007 and 2008
                    (In thousands, except per share data)

                                        Three Months Ended
                                           December 31,    Twelve Months Ended
                                            unaudited          December 31,
                                          2007     2008       2007      2008

    Revenues:
       Net product sales                 $26,202  $65,956   $86,802  $251,851
       Collaborative agreement revenues   17,506   31,518    28,264    38,907
       Royalty and license fee revenues    1,146    1,803     6,515     5,735
          Total revenues                  44,854   99,277   121,581   296,493

    Operating expenses:
       Cost of sales (excludes
        amortization)                      5,224   11,665    18,359    52,509
       Research and development           24,015   25,733    78,600    93,291
       Selling, general and
        administrative                    23,891   28,730    77,539   106,566
       Amortization of intangible assets   1,093    1,093     4,371     4,371

          Total operating expenses        54,223   67,221   178,869   256,737

    Income (loss) from operations         (9,369)  32,056   (57,288)   39,756

    Equity in the income (loss) of
     BioMarin/Genzyme LLC                  9,366     (579)   30,525    (2,270)
    Interest income                        7,383    3,231    25,932    16,388
    Interest expense                      (4,080)  (4,096)  (14,243)  (16,394)
    Impairment loss on investment             --   (4,056)       --    (4,056)

    Income (loss) before income taxes      3,300   26,556   (15,074)   33,424
    Income Taxes                             729    2,050       729     2,593

          Net income (loss)               $2,571  $24,506  $(15,803)  $30,831
          Net income (loss) per share,
           basic                           $0.03    $0.25    $(0.16)    $0.31
          Net income (loss) per share,
           diluted                         $0.03    $0.21    $(0.16)    $0.29
    Weighted average common shares
     outstanding, basic                   96,931   99,777    95,878    98,975
    Weighted average common shares
     outstanding, diluted                101,193  128,296    95,878   103,572


The following is the stock-based compensation expense included in the respective captions of the consolidated statements of operations above:

                                           Three Months
                                              Ended         Twelve Months
                                           December 31,         Ended
                                            unaudited        December 31,
                                           2007    2008     2007     2008

    Cost of sales                           $162    $503     $578   $1,521
    Selling, general and administrative
     expense                               3,092   4,471   10,727   15,145
    Research and development expense       2,211   2,466    6,978    8,584
    Total stock-based compensation
     expense                              $5,465  $7,440  $18,283  $25,250

'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved


Related biology technology :

1. BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
2. BioMarin to Present at the Piper Jaffray Healthcare Conference
3. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
4. BioMarin to Present at the Credit Suisse Healthcare Conference
5. BioMarin Announces Third Quarter 2008 Financial Results
6. BioMarin Corrects Information Included in Bloomberg Article
7. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
8. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
9. BioMarin to Present at the Citi Biotech Day
10. BioMarin Announces Roll-Out of National PKU Registry
11. BioMarin to Host Second Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, August 5 at 5:00 p.m. ET (23:00 CET)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016  Bioethics International, a not-for-profit organization focused ... developed, marketed and made accessible to patients around the world, ... had named the publication of the Good Pharma Scorecard ... is also featured as one of BMJ Open ,s ... year that are most frequently read. Ed Sucksmith ...
(Date:2/11/2016)... 11, 2016 --> ... "Company") (OTCQB: PSID), a life sciences company focused ... Thermomedics subsidiary, which markets the Caregiver® FDA-cleared non-contact ... in January 2016, including entering into agreements with ... sales growth, and establishing several near-term pipeline opportunities. ...
(Date:2/10/2016)... MONTREAL , Febr. 10, 2016 /PRNewswire/ - BioAmber Inc. ... is pleased to announce that Mitsui & Co. Ltd., ... bio-based succinic acid plant, is investing an additional CDN$25 ... equity, increasing its stake from 30% to 40%.  Mitsui ... of bio-succinic acid produced in Sarnia ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... that it has joined the Human Vaccines Project, a public-private partnership to ... cancer. , The Human Vaccines Project brings together leading pharmaceutical and ...
Breaking Biology Technology:
(Date:1/25/2016)... SEATTLE , Jan. 25, 2016  Glencoe Software, ... biotech, pharma and publication industries, will provide the data ... Phenotypic Screening Centre (NPSC). ... Phenotypic analysis ... even whole organisms, allowing comparisons between states such as ...
(Date:1/20/2016)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce the attainment of record-setting ... result of the company,s laser focus on (and growing ... it,s comprehensive, easy-to-use and highly affordable cloud-based technology platform. ... MedNet growth achievements in 2015 include: , ...
(Date:1/13/2016)... January 13, 2016 ... addition of the  "India Biometrics Authentication ... Forecast (2015-2020)"  report to their ... has announced the addition of the  ... - Estimation & Forecast (2015-2020)" ...
Breaking Biology News(10 mins):